<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226693</url>
  </required_header>
  <id_info>
    <org_study_id>A6631028</org_study_id>
    <nct_id>NCT01226693</nct_id>
  </id_info>
  <brief_title>A Study In Healthy Volunteers To Assess The Safety, Tolerability, And Relative Oral Bioavailability Of Three Formulations Of PH-797804</brief_title>
  <official_title>A Phase 1, Randomized, Open Label, Single Dose, 3 Treatment, Two Period, Balanced Incomplete Block Study In Healthy Fasted Volunteers To Assess The Safety, Tolerability, And Relative Oral Bioavailability Of A 6 Mg Dose Of The PH-797804 Material Sparing Tablet (MST) And Two Modified Versions Of The MST Formulation With And Without The Solubilizing Agent Sodium Lauryl Sulphate (SLS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no difference in the rate and extent of absorption of the material sparing tablet
      (MST), the Phase2b/3 formulation (P2b/3) with sodium lauryl sulphate (SLS) and the p2b/3
      formulation without SLS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf)</measure>
    <time_frame>predose to day 7 of treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (AUClast)</measure>
    <time_frame>predose to day 7 of treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration within the dosing interval (Cmax)</measure>
    <time_frame>predose to day 7 of treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time for Cmax (Tmax)</measure>
    <time_frame>predose to day 7 of treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>predose to day 7 of treatment period</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral, 6mg, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral, 6mg, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804 material sparing tablet</intervention_name>
    <description>oral, 6mg, single dose</description>
    <arm_group_label>Sequence 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804 Phase2b/3 with sodium lauryl sulphate</intervention_name>
    <description>oral, 6mg, single dose</description>
    <arm_group_label>Sequence 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804 Phase2b/3 with sodium lauryl sulphate</intervention_name>
    <description>oral, 6mg, single dose</description>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804 material sparing tablet</intervention_name>
    <description>oral, 6mg, single dose</description>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804 material sparing tablet</intervention_name>
    <description>oral, 6mg, single dose</description>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804 Phase2b/3 without sodium lauryl sulphate</intervention_name>
    <description>oral, 6mg, single dose</description>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804 Phase2b/3 without sodium lauryl sulphate</intervention_name>
    <description>oral, 6mg, single dose</description>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804 material sparing tablet</intervention_name>
    <description>oral, 6mg, single dose</description>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804 Phase2b/3 without sodium lauryl sulphate</intervention_name>
    <description>oral, 6mg, single dose</description>
    <arm_group_label>Sequence 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804 Phase2b/3 with sodium lauryl sulphate</intervention_name>
    <description>oral, 6mg, single dose</description>
    <arm_group_label>Sequence 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804 Phase2b/3 with sodium lauryl sulphate</intervention_name>
    <description>oral, 6mg, single dose</description>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804 Phase2b/3 without sodium lauryl sulphate</intervention_name>
    <description>oral, 6mg, single dose</description>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects of non-childbearing potential between the ages of 21
             and 55.

          -  No evidence of active or latent TB.

          -  An informed consent document signed and dated by the subject.

        Exclusion Criteria:

          -  Evidence, including abnormal clinical laboratory parameters, eg, liver enzyme
             elevations, or a history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  Any condition possibly affecting drug absorption (eg, gastrectomy) or any active GI
             disease (including any relevant surgery).

          -  Any current and clinically significant skin lesions as described in Common Terminology
             Criteria for Adverse Events for Dermatology (CTCAE) Version 3. A clinically
             significant skin lesion is defined as Grade 1 (mild) for rash and pruritus, and Grade
             2 (moderate) or above for all other lesions (see Short Name description in CTCAE for
             specific description of lesion).

          -  Use of prescription or nonprescription drugs, vitamins and dietary supplements within
             7 days or 5 half-lives (whichever is longer) prior to the first dose of study
             medication.

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the investigator, would make the subject
             inappropriate for entry into this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6631028&amp;StudyName=A%20Study%20In%20Healthy%20Volunteers%20To%20Assess%20The%20Safety%2C%20Tolerability%2C%20And%20Relative%20Oral%20Bioavailability%20Of%20Three%20Formulations%20Of%20PH-797804</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2010</study_first_posted>
  <last_update_submitted>March 9, 2011</last_update_submitted>
  <last_update_submitted_qc>March 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>pharmacokinetic</keyword>
  <keyword>single dose bioequivalence study</keyword>
  <keyword>balanced incomplete block design</keyword>
  <keyword>PH-797804</keyword>
  <keyword>P38 kinase inhibitor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

